The FDA has approved Auvelity for AD agitation. The combination of dextromethorphan and bupropion is the first oral non-antipsychotic approved for this indication.
Axsome Therapeutics has received the US Food and Drug Administration (FDA) approval for Auvelity (dextromethorphan HBr and ...
WhiteSands Alcohol & Drug Rehab Orlando has published a new educational resource on its website examining the risks associated with not understanding proper dextromethorphan dosage. The article adds ...
AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to ...
FDA cleared the first agent with an NMDA/sigma-1–based mechanism specifically for agitation in Alzheimer’s disease dementia, ...
The FDA expanded the indication for dextromethorphan hydrobromide and bupropion hydrochloride (Auvelity) extended-release ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results